CIK 0001649904 · Large accelerated filer
RHYTHM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RYTM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 462159271
- Phone
- 857-264-4280
- Business address
- 222 BERKELEY STREET, 12TH FLOOR, BOSTON, MA, 02116
- Former names
- RHYTHM METABOLIC, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $11,753,355
- in 2 filings, $11.8M under 10b5-1 plans
Net −$11,753,355. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-14 | Meeker David P President and CEO | Sale 10b5-1 | −6,439 | $101.75 | $655K | 282,819 |
| 2026-09-14 | Meeker David P President and CEO | Sale 10b5-1 | −30,746 | $102.35 | $3.1M | 252,073 |
| 2026-09-14 | Meeker David P President and CEO | Sale 10b5-1 | −8,698 | $103.43 | $900K | 243,375 |
| 2026-09-14 | Meeker David P President and CEO | Sale 10b5-1 | −1,817 | $104.55 | $190K | 241,558 |
| 2026-09-14 | Meeker David P President and CEO | Sale 10b5-1 | −2,300 | $105.19 | $242K | 239,258 |
| 2026-08-31 | Smith Hunter C Chief Financial Officer | Sale 10b5-1 | −23,072 | $104.59 | $2.4M | 153,726 |
| 2026-08-31 | Smith Hunter C Chief Financial Officer | Sale 10b5-1 | −11,514 | $105.37 | $1.2M | 142,212 |
| 2026-08-31 | Smith Hunter C Chief Financial Officer | Sale 10b5-1 | −28,188 | $106.20 | $3.0M | 114,024 |
| 2026-08-13 | Shulman Joseph Chief Technical Officer | Sale 10b5-1 | −5,079 | $119.75 | $608K | 15,915 |
| 2026-08-13 | Garfield Alastair Chief Scientific Officer | Sale 10b5-1 | −2,007 | $116.11 | $233K | 8,051 |
| 2026-08-13 | Garfield Alastair Chief Scientific Officer | Sale 10b5-1 | −1,556 | $117.08 | $182K | 6,495 |
| 2026-08-13 | Garfield Alastair Chief Scientific Officer | Sale 10b5-1 | −3,400 | $118.28 | $402K | 3,095 |
| 2026-08-13 | Garfield Alastair Chief Scientific Officer | Sale 10b5-1 | −800 | $119.17 | $95K | 2,295 |
| 2026-08-13 | Lee Jennifer Kayden EVP, Head of North America | Sale 10b5-1 | −75,834 | $117.38 | $8.9M | 0 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −2,300 | $111.80 | $257K | 110,355 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −1,000 | $112.86 | $113K | 109,355 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −3,605 | $114.70 | $413K | 105,750 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −14,568 | $115.43 | $1.7M | 91,182 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −18,208 | $116.49 | $2.1M | 72,974 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −17,319 | $117.47 | $2.0M | 55,655 |
Page 1 of 6 · 113 trades